Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare’s Fourth Quarter 2025 Earnings Conference Call.
Prestige Consumer Healthcare Inc. (PBH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ariel Investments John W. Rogers | 2,518,941 | $216,553,358 | -9% | 2.54% |
| 2. | Renaissance Technologies Jim Simons | 368,304 | $31,663,095 | +20% | 0.05% |
| 3. | Fisher Asset Management Ken Fisher | 328,060 | $28,203,316 | +5% | 0.01% |
| 4. | D E Shaw D. E. Shaw | 197,193 | $16,952,682 | +41% | 0.02% |
| 5. | Impax Asset Management Ian Simm | 135,000 | $11,605,950 | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.90 | 1,500 | $50,850.00 | 6,600 | 2018-02-12 | Filing | |
| $37.04 | 3,000 | $111,120.00 | 7,806 | 2018-02-07 | Filing | |
| $35.47 | 4,200 | $148,974.00 | 11,097 | 2018-02-05 | Filing | |
| $35.94 | 7,000 | $251,580.00 | 138,969 | 2018-02-05 | Filing | |
| $35.47 | 7,500 | $266,025.00 | 38,506 | 2018-02-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.00 | 1,678 | $151,020.00 | 17,157 | 2025-03-10 | Filing | |
| $85.39 | 6,297 | $537,700.83 | 18,835 | 2025-03-03 | Filing | |
| $86.30 | 5,683 | $490,442.90 | 18,365 | 2025-02-11 | Filing | |
| $86.82 | 5,400 | $468,828.00 | 18,365 | 2025-02-11 | Filing | |
| $82.64 | 5,662 | $467,907.68 | 320,952 | 2024-11-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,182,204 | $703,424,079 | 0.01% | |
| 2. | 5,635,298 | $484,466,569 | 0.01% | |
| 3. | 2,716,712 | $233,550,609 | 0.06% | |
| 4. | 2,252,490 | $193,647,000 | 0.25% | |
| 5. | 1,997,858 | $171,755,852 | 0.01% |
News See All
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2025 Earnings Call Transcript February 6, 2025Prestige Consumer Healthcare Inc. beats earnings expectations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Prestige Consumer Healthcare's Second Quarter 2025 Earnings Call.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Romainy, and I'll prepare your conference operator today.
Should You Invest in Prestige Consumer Healthcare (PBH)?
Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2023 investor letter. A copy of the same can be downloaded here.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q2 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q2 2024 Prestige Consumer Healthcare Earnings Conference Call.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q1 2024 Prestige Consumer Healthcare, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Prestige Consumer Healthcare Fiscal 2023 Earnings Call.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Q3, 2023 Prestige Consumer Healthcare Inc, Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Stocks to Buy in 2022 According to John Rogers' Ariel Investments
In this article, we discuss 10 Stocks to Buy in 2022 According to John Rogers' Ariel Investments.